Oral Proteins and Peptides Market Top Players - AstraZeneca, Biocon Chiasma, Novo Nordisk A/S, Allergan.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Oral Proteins and Peptides Market"-, By Type of Target Disease Indication (Acromegaly, Celiac Disease, Chronic Idiopathic Constipation, Enteric Hyperoxaluria, Inflammatory Bowel Disease, and Type II Diabetes), Type of Molecule (Protein and Peptide), Type of Biological Target (GC-C, Insulin Receptor, Oxalate and others), Type of Mechanism of Action (Receptor Stimulation, Substrate Degradation and Others), and Global Forecasts, 2024-2031 And Segment Revenue and Forecast To 2031."

The Oral Proteins and Peptides Market is estimated to reach over USD 28.17 billion by 2031, exhibiting a CAGR of 20.3% during the forecast period.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2868

Proteins and peptides, as fundamental biological macromolecules, hold considerable therapeutic value for the treatment of a wide array of medical conditions. Over the past three decades-and particularly in the last ten years-there has been significant advancement in the development of protein-based therapeutics, resulting in a substantial increase in the availability of such treatments in the global pharmaceutical market. Nevertheless, the oral administration of these molecules continues to present challenges due to their complex tertiary structures and susceptibility to enzymatic degradation within the gastrointestinal tract.

To address these limitations, ongoing innovation in peptide formulation technologies is enhancing the oral bioavailability of these therapies. Noteworthy developments include the successful clinical progression of therapeutic peptides such as Octreotide, employing Peptelligence® technology, and oral semaglutide, utilizing Eligen® technology. These advancements exemplify the increasing feasibility of oral peptide delivery systems.

Recent technological breakthroughs-such as nanoparticle-based encapsulation, chemical modifications to peptide structures, and the use of permeation enhancers-have demonstrated effectiveness in protecting peptides from gastrointestinal degradation. These innovations are positioning oral peptide therapies as viable, non-invasive alternatives to injectable formulations, significantly improving patient adherence in the management of chronic diseases.

In addition, regulatory incentives such as the U.S. Food and Drug Administration's Fast Track and Breakthrough Therapy designations are accelerating the approval timelines for novel oral peptide drugs, facilitating faster market entry. Strategic collaborations among pharmaceutical companies, biotech firms, and academic research institutions are further driving progress in this field, fostering knowledge sharing and optimizing resource allocation.

The increased investment in research and development across the pharmaceutical and biotechnology sectors is expected to support the discovery of new therapeutic peptides, thus contributing to continued innovation and expansion within the oral protein and peptide therapeutics market.

List of Prominent Players in the Oral Proteins and Peptides Market:
• AstraZeneca
• Biocon Chiasma
• Novo Nordisk A/S
• Allergan
• Oramed Pharmaceuticals
• Proxima Concepts
• Synergy Pharmaceuticals
• Tarsa Therapeutics
• Sanofi
• F. Hoffmann-La Roche Ltd
• Novo Nordisk A/S
• Abbvie Inc.
• Pfizer Inc.
• Bausch Health Companies Inc.
• Chiesi Farmaceutici S.P.A.
• Acadia Pharmaceuticals Inc.
• Aurinia Pharmaceuticals Inc.
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Swk Holdings
• R-Pharm Jsc
• Entera Bio Ltd.
• Proxima Concepts
• Astrazeneca Plc
• Regor Therapeutics Group
• Terns Pharmaceuticals, Inc.
• Structure Therapeutics
• Viking Therapeutics
• Protagonist Therapeutics Inc.
• Rani Therapeutics
• Carmot Therapeutics, Inc.
• Zealand Pharma
• Sciwind Biosciences Co., Ltd.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics
Drivers:
Significant advancements in drug delivery technologies-such as nanoparticle-based carriers, enteric coatings, and enzyme inhibitors-have greatly improved the stability and bioavailability of proteins and peptides, thereby enhancing the feasibility of oral administration. The increasing global burden of chronic diseases, including diabetes, cancer, and endocrine disorders, is fueling demand for more effective, non-invasive treatment modalities. Regulatory agencies, including the U.S. Food and Drug Administration (FDA), have shown growing support for innovative oral protein and peptide therapeutics, which has bolstered investor confidence and stimulated further research and development. Oral formulations currently in development, including those for insulin and other peptide-based treatments, offer a patient-centric alternative to injectable therapies, improving adherence and quality of life. These innovations are well-positioned to address the expanding need for accessible, user-friendly treatments for chronic conditions. Additionally, the rising global geriatric population-more susceptible to such diseases-is contributing to increased demand for advanced, easy-to-administer therapeutic options, thereby driving market growth.

Challenges:
Despite technological progress, developing stable and efficacious oral protein and peptide formulations remains inherently complex. These formulations often require sophisticated delivery systems-such as encapsulation technologies or structural modifications-that increase both development costs and time to market. A major barrier to oral peptide administration continues to be the low bioavailability caused by enzymatic degradation in the gastrointestinal tract and the acidic environment of the stomach, which limits therapeutic efficacy.

Regional Trends:
North America is projected to retain a dominant share of the global market throughout the forecast period, supported by robust investment in research and development and substantial funding from pharmaceutical and biotechnology sectors focused on peptide-based therapies. Regulatory advantages-such as the FDA's Fast Track and Breakthrough Therapy designations-also facilitate expedited approvals for novel oral therapeutics. Conversely, the Asia-Pacific region is anticipated to register the highest growth rate, driven by rising healthcare expenditures, an expanding patient base, and growing awareness of peptide therapeutics. Regulatory modernization in key emerging markets is accelerating drug approvals. Moreover, increased investment in biotechnology sectors across countries such as China and India is bolstering research activities and fostering the development of innovative oral peptide therapies.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2868

Recent Developments:
• In June 2023, Pfizer Inc. declared its intention to proceed with the clinical development of a single oral late-stage glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate for the possible treatment of people with Type 2 diabetes mellitus (T2DM) and obesity. Subject to the outcomes of the ongoing Phase 2 trial, the company will proceed with the clinical development of lotiglipron (PF-07081532) and continue to advance the clinical program for danuglipron (PF-06882961). The business is working on a once-daily modified release version of danuglipron and anticipates having preparations for the late-stage program finalized by the end of 2023.
• In August 2023, Entera Bio, presented abstracts at the annual conference of the American Society for Bone and Mineral Research (ASBMR) on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the treatment of postmenopausal women at high risk of fracture.

Segmentation of Oral Proteins and Peptides Market.
Global Oral Proteins and Peptides Market- Type of Target Disease Indication
• Acromegaly
• Celiac Disease
• Chronic Idiopathic Constipation
• Enteric Hyperoxaluria
• Inflammatory Bowel Disease
• Type II Diabetes
Global Oral Proteins and Peptides Market - Type of Molecule
• Protein
• Peptide
Global Oral Proteins and Peptides Market - Type of Biological Target
• GC-C
• Insulin Receptor
• Oxalate
• Others
Global Oral Proteins and Peptides Market - Type of Mechanism of Action
• Receptor Stimulation
• Substrate Degradation
• Others
Global Oral Proteins and Peptides Market - By Region
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/oral-proteins-and-peptides-market/2868

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.